Novo Nordisk strikes deal with French Biocorp to develop add-on device for insulin pen

French company Biocorp has signed a deal with Novo Nordisk concerning development and potential distribution of a so-called "smart add-on device" to Novo's pre-filled insulin pen Flextouch.

Photo: Tidsvilde Stine/Ritzau Scanpix

Novo Nordisk continues to raise arms on the digital diabetes front. The French company Biocorp, which also collaborates with other pharmaceutical giants, informs that it has entered into an agreement with the Danish pharmaceutical company about the development and possible distribution of a "smart add-on device" to the pre-filled insulin pen Flextouch.

According to Biocrop, the new smart add-on device is a specific version of the company's already existing device, Mallya, a bluetooth enabled device that can collect information about doses as well as times of injection, thus making Novo's Flextouch a smart insulin pen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs